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Abstract
Cell type origin is one of the factors that determine molecular features of tumors, but resources to 
validate this concept are scarce because of technical difficulties in propagating major cell types of 
adult organs. Previous attempts to generate such resources to study breast cancer have yielded 
predominantly basal-type cell lines. We have created a panel of immortalized cell lines from core 
breast biopsies of ancestry-mapped healthy women that form ductal structures similar to normal 
breast in 3D cultures and expressed markers of major cell types including the luminal-
differentiated cell-enriched ERα-FOXA1-GATA3 transcription factor network. We have also 
created cell lines from PROCR (CD201)+/EpCAM- cells that are likely the “normal” counterpart 
of the claudin-low subtype of breast cancers. RNA-seq and PAM50 intrinsic subtype clustering 
identified these cell lines as the “normal” counterparts of luminal A, basal, and normal-like 
subtypes and validated via immunostaining with basal-enriched KRT14 and luminal-enriched 
KRT19. We further characterized these cell lines by flow cytometry for distribution patterns of 
stem/basal, luminal-progenitor, mature/differentiated, multi-potent PROCR+ cells, and 
organogenesis-enriched epithelial/mesenchymal hybrid cells using CD44/CD24, CD49f/EpCAM, 
CD271/EpCAM, CD201/EpCAM, and ALDEFLUOR assays and E-Cadherin/Vimentin double-
staining. These cell lines showed inter-individual heterogeneity in stemness/differentiation 
capabilities and baseline activity of signaling molecules such as NF-κB, AKT2, pERK, and 
BRD4. These resources can be used to test the emerging concept that genetic variations in 
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regulatory regions contribute to widespread differences in gene expression in ‘normal’ conditions 
among the general population and can delineate the impact of cell type origin on tumor 
progression.
Introduction
Normal breast epithelial cells are hierarchically organized broadly into bipotent mammary 
stem/basal (MaSCs), luminal progenitor, and mature/differentiated luminal cells (1,2). 
Luminal progenitor cells have been further classified into bipotent and committed progenitor 
cells based on cell surface marker profiles and expression patterns of keratins (2). While 
basal cells express keratin 14 (KRT14) and luminal cells express keratin 19 (KRT19), cells 
expressing both keratins show luminal progenitor phenotype (3). Each of these cell types is 
associated with distinct transcription factor networks; TP63 and NFIB in basal cells, ELF5 
and EHF in luminal progenitors, and ESR1 and FOXA1 in luminal cells (4). Although 11 
different cell types have been described, it is acknowledged that current methods of sorting 
and classifying cell types based on surface markers and keratin expression may 
underestimate the level of heterogeneity in the normal breast (5). Furthermore, recent studies 
have identified inter-individual genetic variations in non-coding regions affecting gene 
expression across tissues, thus supporting the concept of inter-individual variability in the 
normal breast (6–8). Therefore, a clear understanding of the normal breast heterogeneity and 
signaling pathway differences is needed for better classification of breast tumors and for 
assessing tumor heterogeneity.
Breast cancers have been sub-classified into five intrinsic subtypes based on gene expression 
patterns in tumors (9). These include estrogen receptor alpha (ERα)-positive luminal A and 
luminal B subtypes, HER2+ subtype, basal-subtype and normal-like subtype. Another 
relatively rare molecular subtype called the claudin-low has been added subsequently, which 
is believed to originate from MaSCs (10). It is suggested that bipotent progenitor or luminal 
progenitors are the cell-type-origin of basal breast cancers (11). HER2+ tumors may arise 
from late luminal progenitors, whereas luminal A and luminal B breast cancers may 
originate from differentiated luminal cells (11). Experimental validation of these possibilities 
is still challenging because most of the prior culturing methods favored the outgrowth of 
basal-like breast epithelial cells and primary cells need to be directly used for transformation 
to obtain tumors with luminal and basal-like characteristics (12). Indeed, the most 
commonly used human mammary epithelial cells (HMECs) and MCF10A cells have basal-
like gene expression pattern and transformation of these cells gives rise to squamous cell 
carcinomas instead of adenocarcinomas (13,14). Only one study has reported a method to 
generate cells with luminal characteristics and transformed counterpart of these cells giving 
rise to tumors resembling human breast adenocarcinomas (13). For unknown reasons, this 
methodology has not been adapted widely.
The majority of “normal” tissue for breast cancer-related studies is derived from reduction 
mammoplasty or tissues adjacent to normal. However, a recent study that compared normal 
breast tissue donated by healthy volunteers to Komen Normal Tissue Bank at the Indiana 
University, reduction mammoplasty, and tumor adjacent normal tissues found significant 
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levels of histologic abnormalities in reduction mammoplasty as well as in tumor-adjacent 
normal specimens (15). Additionally, “normal” tissue adjacent to tumors undergoes 
extensive DNA methylation changes, specifically targeting transcription factor binding sites 
specifying chromatin architecture and stem cell differentiation pathways including Wnt and 
FGF signaling networks, due to “field effects” attributed to tumors (16). Thus, although 
several publications in literature have described generation of breast epithelial cell lines 
using tissues from reduction mammoplasty (12,17–26), these cell lines are less likely 
suitable for mechanistic studies because of inherent genomic abnormalities and limited 
luminal cell features. Moreover, a maximum of four cell lines were created in each of these 
studies, which may not be sufficient to study inter-individual variations in signaling 
pathways downstream of specific genomic aberrations. The mechanistic studies in breast 
cancer field, therefore, would benefit from having multiple normal/immortalized cells with 
luminal characteristics from healthy women to critically evaluate interplay between cell-
type-origin, inter-individual differences in normal genome, and cancer-specific genomic 
aberrations driving tumor growth.
We recently reported a modified epithelial reprogramming growth condition that allowed 
propagation of breast epithelial cells with stem/basal, luminal progenitor, and differentiated/
mature cell characteristics from core breast biopsies of healthy women (27). We reported 
significant inter-individual variability in terms of specific cell types and an enrichment of 
PROCR (CD201)+/EpCAM- subpopulation of cells in women of African Ancestry. Here we 
describe creation of a panel of immortalized breast epithelial cell lines with gene expression 
pattern closely resembling the intrinsic subtypes of breast cancer and with features of cells 
prevalent during organogenesis (28). This resource will be made available to research 
community with the goal to address critical issues related to interplay between cell-type-
origin and specific genomic aberration driving breast cancer and to provide diversity in 
“normal” cell types reflecting inter-individual variation and response to exogenous stimuli.
Materials and Methods
Primary cell culture and immortalization
Primary breast epithelial cells were created from fresh or cryopreserved, de-identified 
normal breast tissues of healthy Caucasian, Hispanic and African American women donated 
to the Komen Tissue Bank (KTB) after informed written consent from subjects. All 
experiments were carried out in accordance with the approved guidelines of the Indiana 
University Institutional Review Board. International Ethical Guidelines for Biomedical 
Research Involving Human Subjects were followed. Tissues were dissociated using a 10% 
collagenase/hyaluronidase mixture (#07919, Stem Cell Technologies) and 10 μM ROCK 
inhibitor (ALX-270–333-M005, Enzo Life Sciences) in culture media for two hours at 37°C. 
The dissociated cells were filtered through sterile 70-micron filter, washed in media and 
centrifuged for 5 minutes at 1000 RPM. The cells were co-cultured on irradiated murine 
embryonic fibroblasts (Applied StemCell, Inc.) using media described previously (27). Cells 
were immortalized by human telomerase gene (hTERT) retrovirus using the vector pLXSN-
hTERT. Retrovirus was prepared using the amphophoenix cells and primary cells were 
infected with viral supernatant along with 8 μg/ml polybrene (H9268, Sigma-Aldrich) for 4 
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hours and immortalized cells were selected by 100 μg/ml G418 (61–234, Corning). Since all 
cell lines are derived from normal breast tissues and are not established cell lines, 
authentication is not possible. However, based on karyotyping (Figure S1A), it is clear that 
these are not contaminating established cell lines. Most of the cell lines used are <20 
passages. Cell lines in the laboratory are typically tested for mycoplasma once in two years.
Genetic ancestry mapping and genotype analysis
Leukocyte DNA was obtained from the KTB. Blood was collected using the BD-Vacutainer 
spray-coated K3EDTA tubes (Becton Dickinson). Tubes were centrifuged for 15 min at 
2000 RPM. Once the upper phase (plasma) was removed, the tubes were stored in −80oC. 
Peripheral blood leukocyte DNA was extracted using AutoGenprep 965 (Autogen, Inc.). 
Genotyping was performed using the KASP technology (LGC Genomics) and a 41-SNP 
panel (labeled 41-AIM panel) selected from Nievergelt et al, (29). Genotype analysis using 
the 41 SNPs panel along with a Bayesian clustering method (Structure Software V2.3.4) was 
able to discern continental origins including European (Caucasian)/Middle East, East Asia, 
Central/South Asia, Africa, Americas, and Oceania. A reference set was obtained from the 
Human Genome Diversity Project (HGDP).
RNA sequencing
The concentration and quality of total RNA samples were first assessed using Agilent 2100 
Bioanalyzer. A RIN (RNA Integrity Number) of five or higher was required to pass the 
quality control. 500 nanograms of RNA per sample were used to prepare dual-indexed 
strand-specific cDNA library using TruSeq Stranded mRNA Library Prep Kit (Illumina). 
The resulting libraries were assessed for its quantity and size distribution using Qubit and 
Agilent 2100 Bioanalyzer. 200 picomolar pooled libraries were utilized per flowcell for 
clustering amplification on cBot using HiSeq 3000/4000 PE Cluster Kit and sequenced with 
2×75bp paired-end configuration on HiSeq4000 (Illumina) using HiSeq 3000/4000 PE SBS 
Kit. A Phred quality score (Q score) was used to measure the quality of sequencing. More 
than 90% of the sequencing reads reached Q30 (99.9% base call accuracy).
The sequencing data were first assessed using FastQC (Babraham Bioinformatics) for 
quality control. All sequenced libraries were mapped to the human genome (UCSC hg19) 
using STAR RNA-seq aligner with the following parameter: “--outSAMmapqUnique 60”. 
The reads distribution across the genome was assessed using bamutils (from ngsutils) (30). 
Uniquely mapped sequencing reads were assigned to hg19 refGene genes using 
featureCounts (from subread) with the following parameters: “-s 2 –p –Q 10”. Genes with 
read count per million (CPM) > 0.5 in more than three of the samples were kept. The data 
were normalized using TMM (trimmed mean of M values) method. Differential expression 
analysis was performed using edgeR R package (31). False discovery rate (FDR) was 
computed from p-values using the Benjamini-Hochberg procedure. The multi-dimensional 
scaling (MDS) plot was drawn using plotMDS function in edgeR to visualize the differences 
between the expression profiles of different samples in two dimensions. Raw sequencing 
data have been submitted to GEO (accession number GSE108541).
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Predictor Analysis of Microarray (PAM50) classification
Gene expression was averaged from three replicates for each cell line. Based on the nearest 
PAM50 centroid algorithm, intrinsic breast cancer subtypes were assigned using the 
Pam50.robust model from genefu R package (32). Luminal cell line MCF7 and basal cell 
lines human mammary epithelial cells (HMEC) and MCF10A were included as controls. 
Unsupervised hierarchical clustering of PAM50 gene was performed and shown by using the 
function of heatmap.2 in gplots R package.
Heatmap of pairwise comparison of cell lines
Differential expression analysis was performed between every two different cell lines. A 
total of 11,722 genes with FDR < 0.01 and absolute value of fold change > 1 in any pairwise 
comparison was selected for unsupervised hierarchical clustering.
Flow cytometry, Flow cytometry imaging and Data analysis
Breast epithelial cells were collected by trypsinization, stained using antibodies CD49f-APC 
(FAB13501A), AXL-APC (FAB154A) (R&D Systems), PROCR (CD201)-PE (130–
105-256), EpCAM-PE (130–091-253), EpCAM-APC (130–091-254), EpCAM- VioBlue 
(130–097-324) (Miltenyi Biotech Inc.), CD271-APC (345108) (Biolegend), CD44-APC 
(559942), CD24-PE (555428) (BD Pharmingen), Pan-Cytokeratin-FITC (F3418) (Sigma 
Aldrich) and ALDEFLUOR (01700) (STEMCELL Technologies), and were acquired using 
a BD LSR II flow cytometer. Data were analyzed using CellQuest or FlowJo software. 
Forward and side scatter were used to ensure that only live cells were considered in the 
analysis. Gating was done using appropriate FITC (555573), PE (555749), APC (555576) 
(BD Pharmingen) and VioBlue (130–094-670) (Miltenyi Biotech) isotype control antibodies 
and only a representative isotype control for two fluorescent markers are shown.
For imaging flow cytometry, 500,000–1,000,000 cells per sample were stained with the 
following conjugated antibodies: 1:100 mouse anti-Vimentin Clone V9-Cy3, (C-9080, 
Sigma-Aldrich), and 1:20 mouse anti-CD324/E-Cadherin Clone 67A4-APC, (A15717, 
Molecular Probes). The nucleus was stained with 1:5000 Hoechst 33342 (H-3570, 
Molecular Probes). Cells were fixed and permeabilized using BD Cytofix/Cytoperm solution 
(51–2090KZ, BD Bioscience) for 20 minutes at 4°C. Blocking was done with 5% goat 
serum in 1X BD Perm/Wash solution (51–2091KZ, BD Bioscience) for 15 minutes at 4°C. 
Single color control samples and cocktail sample with all the antibodies were incubated for 
30 minutes at 4°C in dark. Cells were washed twice for 5 minutes between each step with 1x 
BD Perm/Wash solution. The last step of washing was done twice with 1x PBS to eliminate 
the detergent from the cell suspension. Cells were transferred to the UltraClear boil proof 
microcentrifuge tubes (Inc-607-GMT, Dot Scientific). The stained cells were stored in 1% 
formalin in dark at 4°C. 5000 images were analyzed using ImageStream Data Exploration 
and Analysis Software (IDEAS). In-focus cells were evaluated after gating on live single 
cells based on an aspect ratio near 1 and a low area of the bright field.
Antibodies and Western blotting analysis
Primary antibody against p16 (ab108349) was purchased from Abcam. An antibody against 
ERK (sc-94) was purchased from Santa Cruz Biotechnologies. Antibodies against pERK 
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(9101), AKT1 (2967), AKT2 (5239), pAKT1 (9018), pAKT2 (8599), AKT (9272) and 
BRD4 (13440) were purchased from Cell Signaling Technologies. Antibody against E-
cadherin (610181) was purchased from BD Biosciences. Antibody against Vimentin 
(C9080) and β-actin (A5441) were purchased from Sigma-Aldrich. Horseradish peroxidase 
(HRP) linked secondary antibodies against mouse, rabbit and goat were purchased from 
Santa Cruz Biotechnologies. Cell lysates prepared in radioimmunoassay buffer were 
analyzed by Western blotting as described previously (33).
Mammosphere formation assay and cell proliferation assay
Single cell suspensions were cultured to form mammospheres in ultra-low attachment 6-well 
plate at a density of 5000 cells/mL in MammoCult basal medium (human) supplemented 
with MammoCult proliferation supplement (human), Heparin, 1% penicillin/streptomycin 
(STEMCELL Technologies Inc.), and hydrocortisone. Phase contrast images of 
mammospheres were taken at day 6. For secondary and tertiary cultures, mammospheres 
were collected by centrifugation, washed, trypsinized, filtered through 40μm filter and equal 
number of cells were replated in mammosphere media. Mammospheres were counted using 
ImageJ. For cell proliferation assay, cells were seeded in 96-well plates followed by 
treatment with TGFβ1 (1 ng/ml; 7754-BH, R&D Systems) for 3–4 days. At the end of 
treatment, Bromodeoxyuridine (BrDU) incorporation-ELISA was done using BrDU 
proliferation assay kit (Calbiochem/Millipore) according to the manufacturer’s instructions.
Karyotyping of immortalized cell lines
Metaphase chromosome spreads from KTB cell lines at passage between 10–20 were 
prepared by culturing proliferative cells with 0.05 μg/ml colcemid (10295892001, Sigma-
Aldrich) for 2–12 hrs depending on the cell proliferation rate followed by resuspension in 
hypotonic solution (75 mM KCl) for 15 min at 37 °C. Cells were fixed by resuspension in 
Carnoy’s Fixative (3:1 methanol:acetic acid) onto a clean dry slide and allowed to air dry. 
Fixed cells were stained with Hoechst 33342 (Molecular Probes H-3570) and analyzed 
under microscope. More than five metaphase chromosome spreads were analyzed for each 
cell line.
3D in vitro matrigel, collagen, and hydrogel assays
Eight-chamber cover glass system (155409, Lab-Tek II) was coated with 40 μl of matrigel 
(354234, Corning) per well and incubated for 30 minutes at 37 °C for the gel to solidify. 
6000 cells in 400 μl of overlay media comprising primary cell media with 2% matrigel were 
added to the matrigel coated wells. The media was changed every 3–4 days and cells were 
cultured for 10 to 12 days.
Floating Collagen scaffolds were prepared based on a protocol from Linnemann et al. 2015, 
(34) with some modifications. 5000 cells per well in a 48 well plate were used. The final 
concentration of the rat-tail collagen I (A10483–01, Corning) used for the scaffold was 1.3 
mg/ml. 550 mM of HEPES buffer amounting to 1/10th volume of the collagen was used as a 
neutralizing solution. The neutralizing solution was first added to the cell suspension, 
followed by a quick addition of rat-tail collagen. 200 μL of the collagen-cell mixture was 
immediately plated into 48 well plate kept on ice. The gels were incubated for 1 hour at 
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37ºC to promote polymerization. 500 μL of Mammary Epithelial Basal Medium (CC-3151, 
Lonza) with 3 μM Y-27632 and 10 μM forskolin were carefully added to wells. The gels 
were then detached from the bottom of the well by encircling pipet tip around the edge of 
the gel. The media was changed every 3 days and cells were cultured for up to 10 days. 
After day 3, Y-27632 was withdrawn from the medium.
Floating hydrogel scaffold was prepared based on protocol from Miller et al (35). Briefly, 
10,000 cells per well were used in a 4-chamber slide. 25x extracellular matrix was made by 
adding 0.5 mg/ml laminin (23017015, Thermo Fisher), 0.25 mg/ml hyaluronic acid (385908, 
Millipore), and 0.5 mg/ml fibronectin (33016015, Thermo Fisher) in PBS. The final 
concentration of rat-tail collagen I was 1.3 mg/ml. To make 1 ml of the hydrogel, collagen I 
was first neutralized with 12.5% of 0.1N NaOH followed by the addition of ice cold MEGM 
to make the volume 910 μl. 40 μl of extracellular matrix was quickly added. Lastly, 50 μl of 
cell suspension was added to the mixture and pipetted up and down 3–4 times to uniformly 
distribute the cells in the mixture. 200 μl of the hydrogel mixture was added to the 4-well 
chamber slide kept on ice. The gel was incubated for 1 hour at 37ºC. 1 ml MEGM was 
added after the polymerization was complete. The gels were then detached from the bottom 
of the well by encircling a P200 pipet tip around the edge of the gel. All the steps were done 
on ice. Media was changed twice a week and the cells were cultured for 10–14 days.
RNA extraction and quantitative real-time PCR
Total RNA was isolated using RNeasy Kit (74106, Qiagen) and 1 μg of RNA was used to 
synthesize cDNA with Bio-RAD iScript cDNA Synthesis Kit (170–8891). Quantitative real-
time PCR (qRT-PCR) was performed using Taqman universal PCR mix and predesigned 
gene expression assays with best coverage from Applied Biosystems. The following assays 
were used in our study: ACTB (Hs01060665_g1), ESR1 (Hs01046816_m1), GATA3 
(Hs00231122_m1), FOXA1 (Hs04187555_m1), FOXC1 (Hs00559473_s1), ZEB1 
(Hs01566408_m1), SNAI1 (Hs00195591_m1), SNAI2 (Hs00161904_m1), TWIST1 
(Hs00361186_m1), TWIST2 (Hs00382379_m1), EHF (Hs00171917_m1) and TP63 
(Hs00978340_m1).
Electrophoretic mobility shift assay (EMSA)
EMSA with whole cell extracts from immortalized cell lines was performed as described 
previously (33). Oligonucleotides with consensus DNA binding sites for NF-κB (E3292), 
AP-1 (E3201), and OCT-1 (E3242) were purchased from Promega Corporation.
Immunofluorescence of monolayer culture and 3D collagen structures
Cells were seeded in monolayer glass bottomed microwell dish (P35G-0–14-C, MatTek 
Corporation) overnight and fixed with 4% paraformaldehyde for 10 minutes at room 
temperature (RT). Cells were blocked with a blocking buffer comprising 5% goat serum in 
1% BSA and 0.1% triton-x-100 in PBS for 1 hour at RT or overnight at 4°C. KRT14 
(ab7800, Abcam) and KRT19 (Abcam, ab52625) primary antibodies were diluted to 1:200 
in the antibody diluents (S0809, Dako) and added to cells for 1.5 hours at RT. Secondary 
goat anti-rabbit Alexa Fluor 555 (A21428, Life Technologies) and secondary rabbit anti-
mouse Alexa Fluor 488 (A11059, Life Technologies) antibodies were diluted to 1:400 and 
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added to cells for 1 hour in dark at RT. Nuclear staining was done with 1:5000 Hoechst 
33342 (H-3570, Molecular Probes) for 5 minutes. Cells were washed 3 times for 2 minute 
each, between every step. Cells were stored in PBS in dark and images were taken within 48 
hours of staining with Olympus FV1000 MPE inverted confocal microscope.
Cells in the collagen and hydrogel scaffolds were rinsed twice for 10 minutes with 0.05% 
Tween 20 in PBS (PBST) and fixed with 4% paraformaldehyde for 20 minutes, followed by 
quenching with 0.15 M glycine for 10 minutes at RT. Cells were permeabilized with 0.15% 
triton-x-100 in PBST at RT overnight and were blocked with 5% goat serum and 5% fetal 
calf serum in PBST for at least 2 hours. KRT14 and KRT19 primary antibodies were diluted 
to 1:200 in PBST and cells were incubated overnight at 4°C. Secondary goat anti-rabbit 
Alexa Fluor 555 and rabbit anti-mouse Alexa Fluor 488 antibodies were diluted to 1:300 and 
added to cells for 2 hour in dark at RT. The nuclei were stained with 1:2500 Hoechst 33342 
for 15 minutes. All steps were carried out on a rocker and cells were washed twice for 10 
minutes with PBST between every step. The stained scaffolds were stored in PBS and 
imaged with Olympus FV1000 MPE inverted confocal microscope by placing the gel on the 
glass surface of the microwell dish with PBS to help the gel stick to the bottom without 
floating. The XLUMPLFLN-W 20x long working distance objective was used to enable 
imaging of cells embedded in the gel and 3D images were processed using Imaris software.
Statistical analyses
All experiments were conducted in three biological replicates. Statistical analyses were 
performed using Prism software program (version 6.0). qPCR, FACS and cell proliferation 
assay were analyzed using one-way ANOVA. P values <0.05 were considered statistically 
significant.
Results
Isolation and immortalization of primary breast epithelial cells:
We generated immortalized cell lines from core biopsies of normal breast by overexpressing 
human telomerase gene (hTERT) in primary cells isolated and propagated under modified 
epithelial reprogramming assay (Figures 1A). To evaluate the ability of immortalized cell 
lines (called KTB cell lines hereafter) to form acini resembling normal breast, we grew cells 
on matrigel. KTB immortalized cell lines formed acini of varying sizes, similar to the acini 
formed by the most commonly used “normal” cell line MCF10A (Figures 1B).
To ensure that KTB cell lines are representative of women of different genetic ancestry, all 
samples were subjected to highly discriminative ancestry informative 41-SNP (single 
nucleotide polymorphism) genomic analyses (29). As shown in Figure 1C, while self-
reported White women were enriched for European ancestry markers (KTB6, KTB34, 
KTB36 and KTB37), expectedly, the self-reported Hispanic women (KTB21, KTB22 and 
KTB26) displayed highly heterogeneous ancestry marker distribution. Four self-reported 
African American women (KTB8, KTB39, KTB40, and KTB42) had inherited >50% of 
African ancestry markers. To ensure diploid nature of immortalized cell lines, karyotype 
analyses were performed after arresting cells at metaphase of the cell cycle by colcemid 
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treatment and, which confirmed 46 chromosomes in all samples (Figure S1A). Several cell 
lines have undergone >20 passages and remained diploid.
Molecular subtype classification of KTB cell lines:
To determine whether gene expression patterns in immortalized KTB cell lines differ from 
the commonly used normal cell lines MCF10A and HMECs, we performed RNA-seq 
analyses. A cell line derived from a BRCA2 mutant carrier 1505–10B was also included in 
the analyses. Principle component analyses (PCA) revealed distinct differences in gene 
expression pattern between KTB cell lines compared to HMEC, MCF10A, and the luminal 
breast tumor cell line MCF7 (Figure 2A). Independent PCA analyses of KTB cell lines 
showed significant differences between cell lines, further confirming inter-individual 
variations in characteristics of “normal” breast cell lines (Figure 2B).
Unsupervised clustering analyses separated KTB cell lines from HMEC and MCF10A with 
the exception of KTB40 and KTB42, which clustered with HMEC and MCF10A (Figure 
2C). Previous studies have shown enrichment of basal cell gene expression pattern in HMEC 
and MCF10A but the KTB cell lines displayed a distinct gene expression pattern compared 
to HMEC and MCF10A cell lines (14). We performed ingenuity pathway analyses of 733 
genes expressed at higher level in KTB luminal cell lines compared to HMEC, MCF10A, 
KTB40, and KTB42 (Table S1, Subcluster genes). Canonical pathways typically enriched in 
luminal cells including ErbB and PAK signaling were elevated in KTB cell lines (11,36) 
(Table S1, IPA_Pathway).
Encouraged by these results, we next determined whether KTB cell lines represent “normal” 
counterparts of intrinsic subtypes of breast cancer. Intrinsic subtypes have been predicted to 
originate from normal counterparts but it has never been demonstrated experimentally (11). 
Using PAM50 model in genefu, we calculated the subtype probability score for each cell 
line. KTB34 represented luminal A, KTB21, KTB22, and KTB36 represented basal and 
KTB26, KTB37, KTB39, and 1505–10B (BRCA2 mutant) represented normal-like subtypes 
(Figures 2D and 2E). These results document the presence of immortalized cells with gene 
expression pattern similar to intrinsic subtypes of breast cancer.
To further characterize KTB cell lines for luminal and basal-enriched gene expression, we 
measured the expression levels of ESR1, FOXA1, GATA3, and FOXC1. While ESR1, 
FOXA1, and GATA3 are expressed predominantly in luminal cells and form a hormone-
responsive lineage-specific transcription factor network, FOXC1 expression identifies cells 
with basal cell-enriched gene expression (37,38). Indeed, all four of these transcription 
factors were expressed at variable levels in KTB cell lines and to our knowledge, this is the 
first report to document immortalized breast epithelial cell lines expressing ESR1, GATA3, 
and FOXA1 (Figure 2F). We also noted another difference in KTB cell lines and general 
observation about immortalization of breast epithelial cells. Immortalization is often 
associated with the loss of cell cycle inhibitor and senescence promoter p16(INK4) (39). 
However, RNA-seq results showed significant expression of p16(INK4) transcripts in KTB 
cell lines. Western blotting also confirmed expression of p16(INK4) in several of KTB cell 
lines (Figure 2G). Thus, immortalized KTB cell lines are unique in their characteristics 
Kumar et al. Page 9
Cancer Res. Author manuscript; available in PMC 2019 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
compared to available cell lines including the expression of luminal-enriched transcription 
factors and p16(INK4).
To rule out the possibility that intrinsic subtype phenotype is acquired during 
immortalization, we performed RNA-seq analyses of primary cells prior to immortalization. 
PAM50 classification identified primary cells with luminal A, luminal B, basal, and normal-
like features (Figure 2H). It does appear that immortalization selects for specific subtypes as 
intrinsic subtype classification prior and after immortalization did not overlap. In particular, 
KTB40 and KTB42 prior to immortalization clustered as “normal-like” subtype. However, 
we do note a caveat in our analyses, as RNA-seq of primary and immortalized cells was 
done at different times due to volume of samples and these comparisons have limitations. 
Nonetheless, our results clearly show that cells derived from the normal breast prior and 
after immortalization have gene expression patterns overlapping the gene expression patterns 
in intrinsic subtypes of breast cancer.
Keratin expression pattern identifies distinct subpopulation of cells within immortalized 
KTB cell lines:
Keratin 14 (KRT14) is typically expressed at higher levels in basal cells, whereas keratin 19 
(KRT19) is expressed in luminal cells. Cells that express both KRT14 and KRT19 (KRT14+/
KRT19+) are considered to have luminal progenitor properties (3). We used 
immunofluorescence to determine expression pattern of these two keratins. Consistent with 
the results of PAM50 classification, the luminal A cell line KTB34 was strongly positive for 
KRT19, similar to MCF7, although low level KRT14 expression was seen in this cell line, 
whereas the basal cell line KTB22 was strongly positive for KRT14 (Figure 3A). The 
normal-like cell line KTB39 was KRT14+/KRT19+.
Phenotypic heterogeneity in immortalized KTB cell lines:
In order to confirm that the immortalized cell lines show the inter-individual variability as 
previously shown for the primary breast epithelial cells (27), we subjected KTB cell lines 
prior to and after immortalization to phenotypic analyses using additional markers that 
define stem/basal, luminal-progenitor, luminal-differentiated, luminal, and basal cells (1). 
CD49f+/EpCAM, CD49f+/EpCAM+, and CD49f-/EpCAM+ cells are described as breast 
stem, luminal progenitor, and mature/differentiated cells, respectively (1). Primary cells 
prior to immortalization showed inter-individual variation in the levels of all three 
populations of cells (Figure S1B). CD44/CD24 staining pattern also confirmed inter-
individual heterogeneity. After immortalization, this variation decreased considerably with 
the majority of cell lines displaying luminal progenitor phenotype (CD49f+/EpCAM+) 
(Figure 3B). However, there was some variation in the intensity of staining as well as the 
presence of CD49f+/EpCAM- stem/basal subpopulation (Figures 3B). CD49f/EpCAM 
staining patterns in immortalized KTB cell lines were different from MCF10A, HMEC and 
MCF7. CD201 (PROCR), which identifies cells with multi-potent stem cell activity in the 
mouse mammary gland (40), was expressed at variable levels in immortalized KTB cell lines 
with few cell lines containing a mix of CD201+/EpCAM+ and CD201-/EpCAM+ cells, 
while the others with only CD201-/EpCAM+ subpopulation (Figure S2). Cell lines showed 
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similar differences in the staining pattern for CD271, which is expressed predominantly in 
basal cells (41) (Figure S2).
CD44/CD24 and ALDEFLUOR staining identify inter-individual differences in normal 
counterparts of breast cancer stem cells that transition between epithelial and 
mesenchymal state:
Recent studies have shown that breast cancer stem cells transition between epithelial and 
mesenchymal state with proliferative epithelial-like stem cells being positive for aldehyde 
dehydrogenase (ALDH) and invasive/quiescent mesenchymal stem-like cells being CD44+/
CD24- (42). Gene expression pattern in epithelial and mesenchymal cancer stem cells are 
remarkably similar to luminal and basal cells of the normal breast. We characterized KTB 
cell lines for the presence of these two subpopulations of cells. While most of the cells in the 
KTB cell lines were CD44+/CD24+, CD44+/CD24- population varied between cell lines 
(Figure 4A). As with CD49f/EpCAM staining pattern, immortalized cells compared to cells 
prior to immortalization showed more homogeneity in CD44/CD24 staining. Significant 
variations in the levels of ALDEFLUOR+ cells were noted between cell lines (Figures 4B 
and S3A). AXL, which has recently been shown to drive EMT and confers resistance to 
PI3K inhibitors (43), was expressed at variable levels in cell lines (Figure S3B). Collectively, 
these multiple assays document enormous inter-individual heterogeneity in the normal 
breast, which is at least partially reflected in immortalized cell lines.
Stemness properties of immortalized cell lines show inter-individual variability:
To determine whether KTB cell lines show inter-individual variability in stemness, we 
performed mammosphere assay in all cell lines. KTB cell lines showed variable size of 
spheres indicating differences in stemness property of each cell line (Figures 4C). 
Mammospheres were subjected to flow cytometry for CD49f/EpCAM, CD201/EpCAM and 
CD44/CD24 expression to distinguish stem, luminal progenitor, basal and mature/
differentiated cells. This assay suggested inter-individual differences in differentiation 
capacity (Figures 4D). For example, CD44 and CD24 staining of mammospheres showed 
inter-individual variability in the ratio between CD44+/CD24−, CD44−/CD24+ and CD44+/
CD24+ cells. Notably, more CD44-/CD24+ cells, which were never observed under 2D 
culture of primary cells before or after immortalization (Figure 4A), (27), were found in 
mammosphere cultures of most of the cell lines (Figure 4D). Similar increase in CD49f-/
EpCAM+ cells, representing mature/differentiated cells, was noted in mammosphere 
cultures of few cell lines (Figure S4). We further confirmed inter-individual differences in 
differentiation under mammosphere condition by comparing the expression levels of ESR1, 
FOXA1, GATA3, and FOXC1 under 2D and mammosphere conditions. The expression 
levels of ESR1, FOXA1, and GATA3 increased substantially in cells from mammosphere 
cultures compared to 2D cultures (Figure 4E). Thus, stemness and differentiation 
capabilities show inter-individual variability and cell lines/assay systems described here are 
useful for assessment at individual level.
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PROCR (CD201)+/EpCAM- cells enriched in African American women correspond to 
naturally occurring ZEB-1 positive cells with epithelial to mesenchymal transition (EMT) 
phenotype:
KTB40 and KTB42 cell lines distinguished themselves from the rest of the cell lines with 
respect to gene expression patterns and cell surface marker profiles. These cell lines were 
derived from African American women. During our efforts to immortalize breast epithelial 
cells from African American women, we consistently observed rapid immortalization of 
cells with EMT features, which overtook colonies with epithelial phenotype. We placed 
additional efforts to characterize these cell lines. These cells at low density displayed 
epithelial morphology but acquired fibroblastic phenotype with increasing density (Figure 
5A). These cell lines contained heterogeneous population of cells with CD201+/EpCAM-, 
CD201-/EpCAM-, CD201+/CD90-, CD201+/CD90+, CD201-/CD90+, and CD44+/CD24- 
cell surface marker profiles (Figure 5B). The majority of cells stained positive for pan-
keratin antibody (Figure 5B). We included CD90 in this analysis because CD90 is expressed 
in MaSC, fibroblasts, adipocytes, and mesenchymal stem cells (44). Unlike other KTB cell 
lines described above, these cells expressed EMT and stemness-associated transcription 
factors ZEB1, TWIST1, TWIST2, SNAI1 and SNAI2 (Figures 5C and 5D) (45,46). KTB40 
and KTB42 did not demonstrate E-Cadherin positivity in western blotting while the 
remaining cell lines expressed significant levels of E-cadherin (Figure 5E). Vimentin 
expression was significantly higher in KTB40 and KTB42 compared to other KTB cell lines.
Lack of E-cadherin but elevated vimentin provided further evidence for EMT features of 
KTB40 and KTB42 cell lines. Since EMT features partially overlap with stemness (47), 
serial dilution mammosphere assay was performed to determine whether KTB40 and 
KTB42 differ in stemness relative to other KTB cell lines. KTB40 and KTB42 displayed 
higher mammosphere forming ability than other KTB cell lines and only these two cell lines 
were able to form tertiary mammospheres (Figure 5F and 5G).
It is puzzling to detect low levels of vimentin expression in our E-cadherin positive KTB cell 
lines. This could be due to the presence of distinct subpopulation of cells expressing either 
E-cadherin or vimentin. Alternatively, there could be a population of cells that express both 
proteins. Recent studies support the concept of epithelial/mesenchymal or luminal/basal 
hybrid cells playing a role in organogenesis and tumor progression (28,48). To distinguish 
between these possibilities, we measured the expression levels of luminal progenitor cell 
enriched EHF and basal cell enriched TP63 transcription factors (4). While KTB40 and 
KTB42 did not express these two genes, the remaining KTB lines expressed variable levels 
of both EHF and TP63 (Figure 5H). The most commonly used HMEC cells expressed only 
TP63. To confirm the presence of hybrid cells, we double stained cells for E-cadherin and 
vimentin and single cells were analyzed by imaging cytometry. A significant number of cells 
in KTB34 cell line were double positive. Interestingly, although western blotting did not 
detect E-Cadherin expression, a small fraction of KTB42 expressed E-cadherin (Figure 
S5A).
Since our cell lines were derived from core biopsies of healthy women, there is a possibility 
that a fraction of cells in our cell lines display myoepithelial features. CD10+/EpCAM- cells 
are considered myoepithelial cells although a recent study showed CD10 positivity of cancer 
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associated fibroblasts (49,50). While KTB40 and KTB42 were CD10+/EpCAM-, the 
remaining cell lines showed variable levels of CD10 positivity without any distinct 
subpopulation with CD10+/EpCAM- phenotype (Figure S5B).
Inter-individual differences in basal activity of select signaling networks:
Since both transcriptome and phenotypic analyses documented inter-individual 
heterogeneity in cell lines, we next examined whether basal signaling events were also 
different in these cell lines. We measured phospho-ERK, phospho-AKT1, phospho-AKT2, 
OCT-1, AP-1 and NF-κB DNA binding activity because intrinsic subtypes are known to 
differ in activity of signaling molecules (51). Phospho-ERK levels varied between cell lines 
with KTB40 and KTB42 containing highest levels of both phospho-ERK1 and the remaining 
cell lines showing variable levels of phospho-ERK2 but very low levels of phospho-ERK1 
(Figure S6A). Phospho-AKT2 levels varied between cell lines, while phospho-AKT1 levels 
were nearly similar between cell lines (Figure S6A). NF-κB DNA binding activity also 
showed cell line variability with KTB40 and KTB42 showing predominant p65:p50 DNA 
binding activity (Figure S6B). OCT-1 and AP-1 DNA binding activity was least variable 
among KTB cell lines with the exception of very little OCT-1 DNA binding activity in 
KTB40 and KTB42 cell lines (Figures S6C and S6D). These results suggest that few of the 
reported activation of signaling pathways in cancer could be due to higher baseline activity 
in cells from which cancer originated instead of acquired changes during transformation.
BET bromodomain (BRD) proteins have recently been identified as major regulators of 
oncogenic transcription factors and BRD4 among them has been targeted therapeutically 
(52). Two isoforms of BRD4 with opposing functions in cancer progression have been 
described; a long isoform with tumor suppressor activity and a short isoform with pro-
metastatic functions (53). KTB cell lines expressed different levels of both long and short 
forms of BRD4 (Figure S6E), which suggest that tumors originating from cells expressing 
short BRD4 isoform are predisposed for metastatic progression.
The effect of transforming growth factor-β (TGFβ) on cell proliferation of KTB cell lines:
TGFβ regulates various biological processes, including cell proliferation, extracellular 
matrix (ECM) synthesis, angiogenesis, immune response, apoptosis, and differentiation (54). 
TGFβ also inhibits proliferation of ERα+ normal breast epithelial cells and it is believed that 
loss of this TGFβ-mediated growth inhibition is essential for the initiation of ERα+ breast 
cancer (55). To determine the effect of TGFβ on cell proliferation, BrDU-incorporation-
ELISA cell proliferation assay was performed. TGFβ1 inhibited proliferation but response 
varied between cell lines with highest inhibition of KTB34, KTB36, KTB37, KTB21, 
KTB26 and moderate inhibition of KTB6, KTB22, and KTB39 (Figure 6A). Note that 
KTB40 and 42, cell lines derived from CD201+/EpCAM- cells, were least sensitive to 
TGFβ1-mediated growth inhibition. However, there was no correlation between intrinsic 
subtype classification of these cell lines and the level of response to TGFβ1. We further 
examined the effect of TGFβ1 on characteristics of the cells with moderate change in 
proliferation by analyzing the levels of CD49f, CD201, CD271 and EpCAM markers with 
and without TGFβ1 treatment. TGFβ1-treated KTB6, KTB21, KTB36, KTB37 and KTB39 
cells contained higher proportion of cells with basal/stem cell characteristics compared to 
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untreated cells as evident from higher number of CD49f+/EpCAM- and CD271+/EpCAM− 
subpopulations (Figures 6B and S7). Also, TGFβ1 had cell line-specific effects on CD49f, 
CD201, CD271 and EpCAM expression (Figure S7). Overall, these results document inter-
individual variability in response to TGFβ1, which includes growth inhibition, 
dedifferentiation or lack of response.
KTB cell lines generate ductal-like structure in 3D in vitro breast development assays:
There is growing interest in developing organoid culture system to evaluate growth 
characteristics and individualized drug screening (56). We used hydrogel and collagen gel 
3D culture models to determine whether KTB cell lines could create structures similar to 
those found in normal breast (34,35). In both hydrogel and collagen scaffolds assays, KTB 
cell lines formed a complex branched tubular structure when cultured for 10–12 days 
(Figures 7A and 7B). These ductal structures had some resemblance to the interlobular ducts 
that form through the process of ductal initiation and branching (Figures 7A and 7B). While 
the outer layer of these structures contained either KRT14+ or KRT14+/KRT19+ cells, the 
inner layer contained few cells that stained only for KRT19+ cells (Figures 7C and 7D). We 
further confirmed that cells in these structures are epithelial by staining for KRT17, which is 
expressed in all epithelial cell types including mature luminal cells or KRT14+/KRT19+ 
luminal progenitor cells (57) (Figure 7E). Collectively, resources reported in this study and 
assays utilized to characterize individual cell lines highlight the need to use a panel of 
“normal” cells from multiple sources as controls in signaling studies.
Discussion
Breast cancer research over many decades benefited from the availability of various breast 
cancer cell lines that maintain genetic and transcriptional features of breast tumors (57). 
However, modeling features of normal breast epithelial cells in vitro has been exceedingly 
difficult because culture conditions favored outgrowth of cells with basal cell gene 
expression patterns with few showing luminal progenitor properties and almost all 
previously generated breast epithelial cell lines (listed in Table S1, labeled Table comparing 
similar studies), including those with gene expression patterns overlapping with intrinsic 
subtypes and luminal progenitor cells, were derived from reduction mammoplasty samples 
or normal tissues adjacent to tumors with aberrant genomes (13,15,16,57). Moreover, these 
cell lines have not been characterized for inter-individual heterogeneity because of limited 
numbers (2–4 immortalized cell lines per study) and have limited luminal characteristics. 
Thus, limitation in culturing methods and tissue resource severely restricted our ability to 
mechanistically examine the role of specific genomic aberrations noted in luminal breast 
cancers, particularly ERα-positive breast cancers (58). For example, PIK3CA mutations are 
more frequently observed in ERα-positive breast cancers but the mechanistic studies to 
identify downstream signaling events in non-transformed cells had to use basal-like 
MCF10A cells that do not express ERα (59). In addition, due to the heterogeneity noted in 
normal breast as well as the observation that most of the SNPs are located in gene regulatory 
regions affecting gene expression in cis or in trans (6), there is a need to use multiple 
isogenic cell lines with and without cancer-specific genome manipulations to identify 
cancer-specific signaling pathways.
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KTB cell lines described in this manuscript fulfill many of the needs of the research 
community. First, these cell lines are derived from biopsies of healthy women and several of 
these cell lines express p16(INK), which allows examination of oncogenic process by 
defined oncogenes with and without p16(INK)-mediated cell cycle and senescence effects. 
Although most of the in vitro studies have suggested that loss of p16(INK) is necessary for 
immortalization and consequently for transformation (39), breast tumors in some patients 
express p16(INK) indicating that its loss of expression is not always needed for 
transformation. Second, under mammosphere growth conditions, several of KTB cell lines 
differentiated into cells that express higher levels of luminal restricted transcription factors 
such as ESR1, FOXA1 and GATA3 as well as CD49f-/EpCAM+ and CD44-/CD24+ 
phenotypes. Recent genomic analyses of several non-transformed and breast cancer cell 
lines have revealed non-existence of cell lines corresponding to luminal A breast cancer 
(57). To our knowledge, immortalized breast epithelial cell lines expressing luminal markers 
have not been described, but we have for the first time demonstrated that the gene expression 
pattern in one of the KTB cell lines (KTB34) is comparable to luminal A breast cancer. 
Third, we have identified cell lines representing basal-like breast cancer. Thus, cell lines 
with luminal- and basal-enriched gene expression patterns can now be used to generate 
isogenic cell lines that overexpress amplicons, with deletion of chromosomal regions or 
mutations unique to specific subtypes of breast cancer. For example, ER+/HER2- tumors are 
enriched for amplification of CCND1 and FGFR1 and mutations in PIK3CA and ESR1 (60). 
HER2/ERBB2+ breast cancers have been classified into at least two distinct subtypes; one 
with luminal-enriched gene expression and other with basal-enriched gene expression 
including strong co-regulation of hypoxia/EGFR/TNFα/TGFβ/STAT3 pathways (61). KTB 
cell lines showed differences in response to TGFβ1, baseline DNA activity of transcription 
factors such as NF-κB and expression levels of pERK, pAKT2 and BRD4. ERBB2 
overexpression studies in multiple “normal” cell lines would help to establish the role of 
cell-type-origin in determining pathways that are co-regulated along with this oncogene. 
Fifth, in a limited number of cases, we have cells prior to immortalization that have been 
cryopreserved and gene expression analyzed, which can be used for sequential 
characterization of genomic/epigenomic changes during immortalization and transformation.
Claudin-low breast cancers and cell lines contain highly motile cells with fibroblastic 
features that have lost the expression of epithelial markers and at the same time gained gene 
expression pattern similar to bone-marrow derived mesenchymal stem cells (57). Cell lines 
derived from CD201+/EpCAM- cells, which are enriched in African American women (27), 
displayed fibroblastic and stromal features together with high expression level of ZEB1, 
TWIST1, TWIST2, SNAI1, SNAI2, vimentin and elevated NF-κB and ERK activity. These 
cell lines also showed enhanced stemness phenotype compared to other KTB cell lines and 
have partial epithelial characteristics, as E-cadherin expression was detectable in a fraction 
of cells. ZEB-1 has previously been shown to induce claudin-low mammary tumors and we 
had demonstrated the ability of NF-κB to induce ZEB1 (62,63). Collectively, these results 
suggest that CD201+/EpCAM- cells are the cell-type-origin of claudin-low breast cancers 
with inherent features of EMT and elevated basal NF-κB activity. Triple negative breast 
cancers (TNBC) have recently been classified into six subgroups with mesenchymal stem-
like subgroup showing resemblance to claudin-low breast cancers (64). This TNBC subtype 
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also contains elevated NF-κB activity and show EMT features. African American women 
develop basal-like and mesenchymal stem-like triple negative breast cancers with higher 
levels of intra-tumor heterogeneity compared to white women (65) and elevated presence of 
CD201+/EpCAM- cells in their normal breast may contribute to an increase in mesenchymal 
stem-like breast cancers.
Overall, the panel of KTB cell lines described in this study would allow us to ask several 
fundamental questions; 1) to what extent inter-individual differences in baseline signaling 
activity impact cancer-specific signaling? 2) can we predict the behavior of tumor based on 
cell type origin, which can be linked back to a specific intrinsic subtype?, and 3) how do we 
define normal gene expression pattern and expression in how many “normal” cell lines need 
to be measured as controls for cancer studies? In this respect, Susan G Komen normal tissue 
bank at Indiana University has cryopreserved >1000 breast biopsies of healthy women with 
richly annotated demographics and basic health data and we have >90% success rate in 
generating primary cells from cryopreserved samples. Having demonstrated feasibility of 
using the cryopreserved tissues to generate cell lines, these resources can be used in future to 
generate additional cell lines and expand the number of “control” cell lines needed for breast 
cancer research.
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Figure 1: Generation of cell lines from core biopsies of ancestry mapped healthy women (KTB 
cell lines).
A) Phase contrast images of KTB cell lines. B) KTB cell lines form acini on matrigel. C) 
Highly discriminative ancestry informative 41-SNP genomic analyses of KTB cell lines 
show expected heterogeneity in Hispanic women (KTB21, KTB22, and KTB26) compared 
to Caucasian (KTB6, KTB34, KTB36, and KTB37) and African American Women (KTB8, 
KTB39, KTB40, and KTB42).
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Figure 2: Classification of KTB cell lines based on PAM50 subtype predictor.
A) PCA analyses of RNA-seq data of all immortalized cell lines including HME, MCF10A 
and MCF7. 1505–10B is a BRCA2 mutant cell line. B) PCA analyses of RNA-seq data of 
KTB cell lines show heterogeneity in gene expression. C) Unsupervised clustering of RNA-
seq data shows distinct gene expression pattern in KTB cell lines except KTB40 and KTB42 
compared to MCF10A and HME. KTB40 and KTB42 clustered with HME and MCF10A. 
D) Classification of KTB cell lines based on PAM50 subtype classifier. E) Subtype 
prediction scores of individual cell lines. F) Expression levels of luminal-enriched ESR1, 
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FOXA1, GATA3, and basal-enriched FOXC1 in different KTB cell lines. G) p16(INK4) 
expression in different cell lines. H) Classification of primary cells prior to immortalization 
based on PAM50 subtype classifier.
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Figure 3: Luminal and basal cell-enriched features of KTB cell lines.
Representative data are presented. A) KRT14 and KRT19 staining patterns of different cell 
lines. MCF10A and MCF7 were used as controls. B) CD49f and EpCAM staining patterns 
of cell lines. CD49f+/EpCAM-, CD49f+/EpCAM+ and CD49f-/EpCAM+ cells correspond 
to stem/basal, luminal-progenitor, and mature-luminal cells, respectively.
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Figure 4: KTB cell lines show different levels of CD44+/CD24- and ALDEFLUOR+ stem cells 
based on culture condition.
A) CD44 and CD24 staining pattern of KTB cell lines. B) ALDEFLUOR+ stem cells in 
different cell lines. C) KTB cell lines form mammospheres of variable sizes. D) Cells in 
mammospheres show different levels of differentiation based on CD44/CD24 staining 
pattern. E) Cells in mammospheres show elevated levels of stem/basal (FOXC1) and luminal 
differentiation markers (ESR1, FOXA1, and GATA3).
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Figure 5: CD201+/EpCAM- cells express pan-keratin but display features of EMT.
A) Confluence-dependent changes in morphology of CD201+/EpCAM- cells. B) CD24, 
CD44, CD90, CD201, EpCAM, and pan-keratin staining pattern of cell lines. C) ZEB1 
expression levels in various KTB cell lines with and without TGFβ1 treatment. ZEB1 
expression in KTB40 and KTB42 was significantly higher than in other KTB cell lines 
(p<0.0001). D) TWIST1, TWIST2, SNAI1 and SNAI2 expression levels in various KTB cell 
lines. A TWIST1, TWIST2, SNAI1 and SNAI2 expression in KTB40 and KTB42 was 
significantly higher than in other KTB cell lines. E. E-cadherin and vimentin expression 
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levels in various KTB cell lines. F) Self-renewal capacity of various cell lines as measured 
by mammosphere assay. Primary mammospheres of KTB40 and KTB42 but not other KTB 
cell lines formed tertiary mammospheres. M P1, mammosphere passage 1; M P2 
mammosphere passage 2; M P3, mammosphere passage 3. G) Mammosphere forming 
efficiency of various KTB cell lines. KTB40 and KTB42 cell lines were more efficient than 
other cell lines in generating mammospheres. H) TP63 and EHF expression levels in various 
KTB cell lines.
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Figure 6: The effect of TGFβ1 on proliferation and differentiation of KTB cell lines.
A) KTB cell lines show variable sensitivity to TGFβ1 in cell proliferation assay. The effects 
indicated by stars are statistically significant but the extent of effects varied between cell 
lines (*p<0.05, **p<0.004, ***p<0.0007, ****p<0.0001. B) The effect of TGFβ1 on cell 
surface markers that define stem/progenitor/mature cell status.
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Figure 7: KTB cell lines form ductal structures under 3D culture conditions.
A) Phase contrast images of hydrogel cultures. B) Phase contrast images of collagen 
cultures. C) KRT14 and KRT19 staining patterns of cells in hydrogel cultures. D) KRT14 
and KRT19 staining patterns of collagen cultures. E) KRT17 staining patterns of collagen 
cultures.
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